HillnerB, IngleJ, ChlebowskiRTet al.ASCO 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol, 2003; 21:4042–4057.
2.
PereiraJ. Management of bone pain. PortenoyRK, BrueraE. Topics in Palliative Care, 3. New York: Oxford University Press, 1998.
3.
BodyJJ, ManciniI. Bisphosphonates for cancer patients: why, how and when?Support Care Cancer, 2002; 10:399–407.
4.
BodyJJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol, 2001; 28,4, Suppl 11:49–53.
5.
StrangP. Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. Acta Oncol, 1996; 35,Suppl 5:50–54.
6.
BerensonJR, RosenLS, HowellAet al.Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer, 2001; 91:1191–1200.
7.
DesHarnaisCL, BajwaK, MarkleJPet al.A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Cancer Care, 2001; 9:545–551.
